Plasma-soluble urokinase-type plasminogen activator receptor levels are associated with clinical and pathological activities in lupus nephritis: A large cohort study from China

Lupus

Volumn 24, Issue 6, 2015, Pages 546-557

  Qin, D D ^a,b   Song, D ^a   Huang, J ^a   Yu, Feng ^a   Zhao, M H ^a,c  

^a PEKING UNIVERSITY FIRST HOSPITAL   (China)

^b HARBIN MEDICAL UNIVERSITY   (China)

^c Tsinghua University   (China)

Author keywords

Lupus nephritis; systemic lupus erythematosus; uPA; uPAR

Indexed keywords

UROKINASE; UROKINASE RECEPTOR;

ADULT; ARTICLE; CHINA; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LUPUS ERYTHEMATOSUS NEPHRITIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RISK FACTOR; SLEDAI; SURVIVAL; BIOPSY; BLOOD; COHORT ANALYSIS; GLOMERULUS FILTRATION RATE; LUPUS NEPHRITIS; PATHOLOGY; PATHOPHYSIOLOGY; PROCEDURES;

ADULT; BIOPSY; CHINA; COHORT STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; LUPUS NEPHRITIS; MALE; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; RISK FACTORS; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 84928007692     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203314558857     Document Type: Article

References (45)

1. Oates JC, Varghese S, Bland AM, et al. Prediction of urinary protein markers in lupus nephritis. Kidney Int. 2005 ; 68: 2588-2592
2. Davidson A, Aranow C. Pathogenesis and treatment of systemic lupus erythematosus nephritis. Curr Opin Rheumatol. 2006 ; 18: 468-475
3. Gigante A, Gasperini ML, Afeltra A, et al. Cytokines expression in SLE nephritis. Eur Rev Med Pharmacol Sci. 2011 ; 15: 15-24
4. May AE, Kanse SM, Lund LR, Gisler RH, Imhof BA, Preissner KT. Urokinase receptor (CD87) regulates leukocyte recruitment via beta 2 integrins in vivo. J Exp Med. 1998 ; 188: 1029-1037
5. Briassouli P, Halushka MK, Reed JH, et al. A central role of plasmin in cardiac injury initiated by fetal exposure to maternal anti-Ro autoantibodies. Rheumatology (Oxford). 2013 ; 52: 1448-1453
6. Wei C, Möller CC, Altintas MM, et al. Modification of kidney barrier function by the urokinase receptor. Nat Med. 2008 ; 14: 55-63
7. Thunø M, Macho B, Eugen-Olsen J. SuPAR: The molecular crystal ball. Dis Markers. 2009 ; 27: 157-172
8. Winkler F, Kastenbauer S, Koedel U, Pfister HW. Role of the urokinase plasminogen activator system in patients with bacterial meningitis. Neurology. 2002 ; 59: 1350-1355
9. Miyake H, Hara I, Yamanaka K, Gohji K, Arakawa S, Kamidono S. Elevation of serum levels of urokinase-type plasminogen activator and its receptor is associated with disease progression and prognosis in patients with prostate cancer. Prostate. 1999 ; 39: 123-129
10. Yilmaz G, Mentese A, Kaya S, Uzun A, Karahan SC, Koksal I. The diagnostic and prognostic significance of soluble urokinase plasminogen activator receptor in Crimean-Congo hemorrhagic fever. J Clin Virol. 2011 ; 50: 209-211
11. Andersen O, Eugen-Olsen J, Kofoed K, Iversen J, Haugaard SB. SuPAR associates to glucose metabolic aberration during glucose stimulation in HIV-infected patients on HAART. J Infect. 2008 ; 57: 55-63
12. Rabna P, Andersen A, Wejse C, et al. Urine suPAR levels compared with plasma suPAR levels as predictors of post-consultation mortality risk among individuals assumed to be TB-negative: A prospective cohort study. Inflammation. 2010 ; 33: 374-380
13. Perch M, Kofoed P, Fischer TK, et al. Serum levels of soluble urokinase plasminogen activator receptor is associated with parasitemia in children with acute Plasmodium falciparum: malaria infection. Parasite Immunol. 2004 ; 26: 207-211
14. Toldi G, Bekõ G, Kádár G, et al. Soluble urokinase plasminogen activator receptor (suPAR) in the assessment of inflammatory activity of rheumatoid arthritis patients in remission. Clin Chem Lab Med. 2013 ; 51: 327-332
15. Toldi G, Szalay B, Bekõ G, et al. Plasma soluble urokinase plasminogen activator receptor (suPAR) levels in systemic lupus erythematosus. Biomarkers. 2012 ; 17: 758-763
16. Enocsson H, Wetterö J, Skogh T, Sjöwall C. Soluble urokinase plasminogen activator receptor levels reflect organ damage in systemic lupus erythematosus. Transl Res. 2013 ; 162: 287-296
17. Enocsson H, Wetterö J, Skogh T, Sjöwall C. Limited value of soluble urokinase plasminogen activator receptor as a disease activity marker in patients with systemic lupus erythematosus. Arthritis Rheum. 2011 ; 63: S556-S557
18. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997 ; 40: 1725
19. Liang MH, Socher SA, Larson MG, Schur PH. Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum. 1989 ; 32: 1107-1118
20. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The committee on prognosis studies in SLE. Arthritis Rheum. 1992 ; 35: 630-640
21. Yu F, Tan Y, Liu G, Wang SX, Zou WZ, Zhao MH. Clinicopathological characteristics and outcomes of patients with crescentic lupus nephritis. Kidney Int. 2009 ; 76: 307-317
22. Wei C, El Hindi S, Li J, et al. Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat Med. 2011 ; 17: 952-960
23. Weening JJ, D'Agati VD, Schwartz MM, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int. 2004 ; 65: 521-530
24. Austin HA 3rd, Muenz LR, Joyce KM, Antonovych TT, Balow JE. Diffuse proliferative lupus nephritis: Identification of specific pathologic features affecting renal outcome. Kidney Int. 1984 ; 25: 689-695
25. Austin HA 3rd, Boumpas DT, Vaughan EM, Balow JE. Predicting renal outcomes in severe lupus nephritis: Contributions of clinical and histologic data. Kidney Int. 1994 ; 45: 544-550
26. Harley JB, Kelly JA, Kaufman KM. Unraveling the genetics of systemic lupus erythematosus. Springer Semin Immunopathol. 2006 ; 28: 119-130
27. Waldman M, Appel GB. Update on the treatment of lupus nephritis. Kidney Int. 2006 ; 70: 1403-1412
28. Moroni G, Radice A, Giammarresi G, et al. Are laboratory tests useful for monitoring the activity of lupus nephritis? A 6-year prospective study in a cohort of 228 patients with lupus nephritis. Ann Rheum Dis. 2009 ; 68: 234-237
29. Ricker DM, Hebert LA, Rohde R, Sedmak DD, Lewis EJ, Clough JD. Serum C3 levels are diagnostically more sensitive and specific for systemic lupus erythematosus activity than are serum C4 levels. The Lupus Nephritis Collaborative Study Group. Am J Kidney Dis. 1991 ; 18: 678-685
30. Kirchheimer JC, Nong YH, Remold HG. IFN-gamma, tumor necrosis factor-alpha, and urokinase regulate the expression of urokinase receptors on human monocytes. J Immunol. 1988 ; 141: 4229-4234
31. Chavakis T, Willuweit AK, Lupu F, Preissner KT, Kanse SM. Release of soluble urokinase receptor from vascular cells. Thromb Haemost. 2001 ; 86: 686-693
32. Weckerle CE, Mangale D, Franek BS, et al. Large-scale analysis of tumor necrosis factor alpha levels in systemic lupus erythematosus. Arthritis Rheum. 2012 ; 64: 2947-2952
33. Montuori N, Ragno P. Multiple activities of a multifaceted receptor: Roles of cleaved and soluble uPAR. Front Biosci (Landmark Ed). 2009 ; 14: 2494-2503
34. Conese M, Nykjaer A, Petersen CM, et al. Alpha-2 macroglobulin receptor/Ldl receptor-related protein(Lrp)-dependent internalization of the urokinase receptor. J Cell Biol. 1995 ; 131: 1609-1622
35. Czekay RP, Kuemmel TA, Orlando RA, Farquhar MG. Direct binding of occupied urokinase receptor (uPAR) to LDL receptor-related protein is required for endocytosis of uPAR and regulation of cell surface urokinase activity. Mol Biol Cell. 2001 ; 12: 1467-1479
36. Nykjaer A, Petersen CM, Møller B, et al. Purified alpha 2-macroglobulin receptor/LDL receptor-related protein binds urokinase.plasminogen activator inhibitor type-1 complex. Evidence that the alpha 2-macroglobulin receptor mediates cellular degradation of urokinase receptor-bound complexes. J Biol Chem. 1992 ; 267: 14543-14546
37. Nykjaer A, Conese M, Christensen EI, et al. Recycling of the urokinase receptor upon internalization of the uPA:serpin complexes. EMBO J. 1997 ; 16: 2610-2620
38. Keeton M, Ahn C, Eguchi Y, Burlingame R, Loskutoff DJ. Expression of type 1 plasminogen activator inhibitor in renal tissue in murine lupus nephritis. Kidney Int. 1995 ; 47: 148-157
39. Fuhrman B. The urokinase system in the pathogenesis of atherosclerosis. Atherosclerosis. 2012 ; 222: 8-14
40. Blasi F, Carmeliet P. uPAR: A versatile signalling orchestrator. Nat Rev Mol Cell Biol. 2002 ; 3: 932-943
41. Sidenius N, Sier CF, Blasi F. Shedding and cleavage of the urokinase receptor (uPAR): Identification and characterisation of uPAR fragments in vitro and in vivo. FEBS Lett. 2000 ; 475: 52-56
42. Andersen O, Eugen-Olsen J, Kofoed K, Iversen J, Haugaard SB. Soluble urokinase plasminogen activator receptor is a marker of dysmetabolism in HIV-infected patients receiving highly active antiretroviral therapy. J Med Virol. 2008 ; 80: 209-216
43. Pliyev BK. Activated human neutrophils rapidly release the chemotactically active D2D3 form of the urokinase-type plasminogen activator receptor (uPAR/CD87). Mol Cell Biochem. 2009 ; 321: 111-122
44. Cheng CC, Lee YF, Lan JL, et al. Mycophenolate mofetil alleviates lupus nephritis through urokinase receptor signaling in a mice model. Lupus. 2013 ; 22: 554-561
45. Wang Y, Yu F, Song D, Wang SX, Zhao MH. Podocyte involvement in lupus nephritis based on the 2003 ISN/RPS system: A large cohort study from a single centre. Rheumatology (Oxford). 2014 ; 53: 1235-1244